Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
Rchr
J-GLOBAL ID：202201002548610617
Update date: Mar. 06, 2025 AJIMIZU HITOMI
アジミズ ヒトミ | AJIMIZU HITOMI
Kyoto University Hospital
About Kyoto University Hospital
Papers (43)：
- Yusuke Shima, Hironori Yoshida, Keiichiro Suminaga, Hiroshi Yoshida, Kentaro Hashimoto, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Funazo, Takashi Nomizo, et al. Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study. BMC Cancer. 2025. 25. 1
- Kazutaka Hosoya, Hiroaki Ozasa, Masahiro Tanji, Hiroshi Yoshida, Hitomi Ajimizu, Takahiro Tsuji, Hironori Yoshida, Yukinori Terada, Noritaka Sano, Yohei Mineharu, et al. Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients. BMC Cancer. 2024. 24. 1
- Daisuke Natori, Hiroaki Ozasa, Yusuke Shima, Chisaki Mizumoto, Keiichiro Suminaga, Takashi Nomizo, Hitomi Ajimizu, Hironori Yoshida, Toyohiro Hirai. Successful treatment of lung cancer coexisting with B-cell lymphoma with pembrolizumab following rituximab-included chemotherapy: A case report. Molecular and Clinical Oncology. 2024. 20. 4
- Yusuke Kataoka, Naoya Tanabe, Masahiro Shirata, Nobuyoshi Hamao, Issei Oi, Tomoki Maetani, Yusuke Shiraishi, Kentaro Hashimoto, Masatoshi Yamazoe, Hiroshi Shima, et al. Artificial intelligence-based analysis of the spatial distribution of abnormal computed tomography patterns in SARS-CoV-2 pneumonia: association with disease severity. Respiratory research. 2024. 25. 1. 24-24
- Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, et al. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer. Molecular Cancer Therapeutics. 2023
- Hitomi Ajimizu, Yuichi Sakamori. Narrative review of indication and management of induction therapy for thymic epithelial tumors. Mediastinum. 2024. 8
- Yoshito Yamada, Masatsugu Hamaji, Harutaro Okada, Akihiro Takahagi, Hitomi Ajimizu, Sho Koyasu, Yuichi Sakamori, Akihiro Aoyama. Re-evaluation and operative indications after induction therapy for thymic epithelial tumors. Mediastinum. 2024. 8
- 吉田博徳, 橋本健太郎, 吉田寛, 味水瞳, 糸谷涼, 阪森優一, 小笹裕晃, 平井豊博. PD-L1高発現のSTK11/TP53/KRAS変異陽性肺腺癌に対して免疫チェックポイント阻害剤を投与した症例. 気管支学. 2023. 45
- 住永圭一郎, 吉田博徳, 名取大輔, 島佑介, 味水瞳, 野溝岳, 小笹裕晃, 阪森優一, 阪森優一, 吉岡正博, et al. 当院における胸部悪性腫瘍に対するComprehensive Genomic Profilingの有用性の検証. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
- Masatoshi Yamazoe, Hiroaki Ozasa, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Yamamoto, Takahiro Tsuji, Ryo Itotani, Yuichi Sakamori, Takashi Nomizo, et al. TEAD single nucleotide polymorphism affects PFS in EGFR-mutation positive lung cancer patients treated with EGFR TKIs. CANCER SCIENCE. 2022. 113. 1014-1014
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
